
We Claim:

1. A composition comprising at least one compound according to Formula I:



Formula I

its stereoisomers and/or pharmaceutically acceptable salts, wherein:

R^1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, $NHSO_2R$, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy;

n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;

R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl;


L_1 is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms, optionally substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl;

R^2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano, or COR^7, wherein R^7 is selected from hydroxy, alkyl, alkoxy, or amine, NHR', $NHSO_2R$, or NHCOR;

Y^1 is oxygen or hydrogen;

Y^2 is optional, and wherein when Y^2 is present, Y^1 and Y^2 are hydrogen and when Y^2 is not present, Y^1 is a carbonyl group.

2. A composition according to Claim 1, wherein the compound is according to Formula II:



Formula II

its stereoisomers and/or pharmaceutically acceptable, wherein:

R^1 and R^7 are independently selected from a group consisting of hydroxy, alkoxy, alkyl, amine, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, $NHSO_2R$ or NHCOR, wherein R is selected from alkyl or cycloalkyl;


n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;

R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl;

L^1 is independently a linear aliphatic chain optionally containing from 6 to 16 carbon-atoms and L^1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl.

3. A composition according to Claim 1, wherein the compound is according to Formula III:



Formula III

its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein:

R^1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, $NHSO_2R$ or NHCOR, wherein R is selected from alkyl or cycloalkyl;


n^1 and n^2 are independently selected from 0, 1, and 2;


at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;


R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl; and


L^1 is a linear aliphatic chain optionally containing from 4 to 16 carbon-atoms and L^1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl. R2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano or COR^7; wherein R^7 is selected from a group consisting of hydroxy, alkyl, alkoxy, amine, NHR', or $NHSO_2R$.


4. The composition according to Claim 1, wherein the compound is selected from one or more of:






;


;


;



;



;



;



;



;



;


;


;







their stereoisomers, pharmaceutically acceptable salts, tautomers, and mixtures thereof.


5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to Claim 1.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to Claim 2.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to Claim 3

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to Claim 4.

9. A method for the treatment of insulin resistance, diabetes, and/or cardiovascular disease in a subject, the method comprising administering to the subject at least one compound according to Formula I:



Formula I

its stereoisomers and/or pharmaceutically acceptable salts, wherein:

R^1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, $NHSO_2R$, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy;

n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;

R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl;


L_1 is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms, optionally substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl;

R^2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano, or COR^7, wherein R^7 is selected from hydroxy, alkyl, alkoxy, or amine, NHR', $NHSO_2R$, or NHCOR;

Y^1 is oxygen or hydrogen;

Y^2 is optional, and wherein when Y^2 is present, Y^1 and Y^2 are hydrogen and when Y^2 is not present, Y^1 is a carbonyl group.

10. The method according to Claim 9, wherein the method comprises administering to the subject a compound according to Formula II:



Formula II

its stereoisomers and/or pharmaceutically acceptable, wherein:

R^1 and R^7 are independently selected from a group consisting of hydroxy, alkoxy, alkyl, amine, NHR' wherein R' is alkyl or cycloalkyl

optionally substituted by hydroxy or alkoxy, $NHSO_2R$ or NHCOR, wherein R is selected from alkyl or cycloalkyl;


n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;

R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl;

L^1 is independently a linear aliphatic chain optionally containing from 6 to 16 carbon-atoms and L^1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl.

11. The method according to Claim 9, wherein the method comprises administering to the subject a compound according to Formula III:



Formula III

its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein:

R^1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, $NHSO_2R$ or NHCOR, wherein R is selected from alkyl or cycloalkyl;


n^1 and n^2 are independently selected from 0, 1, and 2;


at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;


R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl; and


L^1 is a linear aliphatic chain optionally containing from 4 to 16 carbon-atoms and L^1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl. R2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano or COR^7; wherein R^7 is selected from a group consisting of hydroxy, alkyl, alkoxy, amine, NHR', or $NHSO_2R$.


12. The method according to Claim 9, wherein the method comprises administering to the subject a compound selected from one or more of:






;


;


;



;


;



;



;


;



;


;



;



;


;



;



;


;



;


;



;



;



;


;


;


;



;



their stereoisomers, pharmaceutically acceptable salts, tautomers, and mixtures thereof.

CLAIMS

1. A composition comprising at least one compound according to Formula I:



Formula I

its stereoisomers and/or pharmaceutically acceptable salts, wherein:

R^1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, $NHSO_2R$, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy;

n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;

R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl;


L_1 is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms, optionally substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl;

R^2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano, or COR^7, wherein R^7 is selected from hydroxy, alkyl, alkoxy, or amine, NHR', $NHSO_2R$, or NHCOR;

Y^1 is oxygen or hydrogen;

Y^2 is optional, and wherein when Y^2 is present, Y^1 and Y^2 are hydrogen and when Y^2 is not present, Y^1 forms a carbonyl group.

2. A composition according to Claim 1, wherein the compound is according to Formula II:



Formula II

its stereoisomers and/or pharmaceutically acceptable, wherein:

R^1 and R^7 are independently selected from a group consisting of hydroxy, alkoxy, alkyl, amine, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, $NHSO_2R$ or NHCOR, wherein R is selected from alkyl or cycloalkyl;


n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;

R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl;

L^1 is independently a linear aliphatic chain optionally containing from 6 to 16 carbon-atoms and L^1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl.

3. A composition according to Claim 1, wherein the compound is according to Formula III:



Formula III

its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein:

R^1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, $NHSO_2R$ or NHCOR, wherein R is selected from alkyl or cycloalkyl;


n^1 and n^2 are independently selected from 0, 1, and 2;


at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;


R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl; and


L^1 is a linear aliphatic chain optionally containing from 4 to 16 carbon-atoms and L^1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl. R2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano or COR^7; wherein R^7 is selected from a group consisting of hydroxy, alkyl, alkoxy, amine, NHR', or $NHSO_2R$.


4. The composition according to Claim 1, wherein the compound is selected from one or more of :



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;






;



;


;


;


;



their stereoisomers, pharmaceutically acceptable salts, tautomers, and mixtures thereof.


5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to Claim 1.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to Claim 2.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to Claim 3.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to Claim 4.

9. Use of compound in the manufacture of a medicament in the treatment of insulin resistance, diabetes, and/or cardiovascular disease in a subject, the compound comprising at least one compound according to Formula I:



Formula I

its stereoisomers and/or pharmaceutically acceptable salts, wherein:

R^1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, $NHSO_2R$, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy;

n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;

R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl;


L_1 is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms, optionally substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl;

R^2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano, or COR^7, wherein R^7 is selected from hydroxy, alkyl, alkoxy, or amine, NHR', $NHSO_2R$, or NHCOR;

Y^1 is oxygen or hydrogen;

Y^2 is optional, and wherein when Y^2 is present, Y^1 and Y^2 are hydrogen and when Y^2 is not present, Y^1 is a carbonyl group.

10. The use according to claim 9, the compound comprising a compound according to Formula II:



Formula II

its stereoisomers and/or pharmaceutically acceptable, wherein:

R^1 and R^7 are independently selected from a group consisting of hydroxy, alkoxy, alkyl, amine, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, $NHSO_2R$ or NHCOR, wherein R is selected from alkyl or cycloalkyl;


n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;

R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl;

L^1 is independently a linear aliphatic chain optionally containing from 6 to 16 carbon-atoms and L^1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl.

11. The use according to Claim 9, the compound comprising a compound according to Formula III:



Formula III

its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein:

R^1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHR' wherein R' is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, $NHSO_2R$ or NHCOR, wherein R is selected from alkyl or cycloalkyl;


n^1 and n^2 are independently selected from 0, 1, and 2;

at least one of R^3 and R^4 and/or R^5 and R^6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO_2;


R^3 and R^4 or R^5 and R^6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl; and

L^1 is a linear aliphatic chain optionally containing from 4 to 16 carbon-atoms and L^1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl. R2 is independently selected from hydrogen, alkoxy, hydroxy, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cyano or COR^7; wherein R^7 is selected from a group consisting of hydroxy, alkyl, alkoxy, amine, NHR', or $NHSO_2R$.


12. The use according to Claim 9, the compound comprising a compound selected from one or more of:




;




;





;





;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;


;



;


;



;



;



;



;







their stereoisomers, pharmaceutically acceptable salts, tautomers, and mixtures thereof.